Application of benzamide derivative to preparing antitumor drug

Abstract

The invention belongs to the gene engineering and chemical field and relates to application of FD4: N-(3-(benzamide)-5-(4-oxo-4H-3,1-benzoxazine-2-yl) phenyl) benzamide to preparing an antitumor drug. The FD4 can obviously inhibit proliferation of tumor cells, is a drug designed aiming to a cell target CYPJ (Cyclophilin J), is not easy to cause the drug resistance and also has special and obvious effect to the tumor cells of a high expression CYPJ protein. Therefore, a small molecular compound is developed as a novel antitumor drug and has obvious tumor killing effect and good specificity, and the FD4 can be developed as the novel antitumor drug and provides a new way and means to treat and cure the tumor.

Description

Technical field

[0001] The present invention relates to the field of chemical industry and medicine, and relates to N-[3-(benzamide)-5-(4-oxo-4H-3,1-benzoxazin-2-yl)phenyl]benzamide Application in the preparation of anti-tumor drugs. Background technique

[0002] Cycliphilins (CyPs) are ubiquitously distributed intracellular proteins that exist in plants, bacteria and mammals. They are highly conserved and were originally discovered as cell receptors for cyclosporin A. Cyclosporin A (Cyclosporin A, CsA) is a cyclic peptide containing 11 amino acids isolated from fungal metabolites. It is an immunosuppressant used in organ transplantation and autoimmune diseases. It has been widely used in clinical practice. , With annual sales of more than US$5 billion. Since CsA has been used in clinical practice, it has shown various toxic and side effects, and its impact on the survival rate of patients and grafts has attracted more and more attention. Many scientific researchers are trying ...

Images